Abstract

Dendritic cells (DCs) control adaptive immunity and are therefore attractive for in vivo targeting to either induce immune activation or tolerance, depending on disease. Liposomes, nanoparticles comprised of a lipid bi-layer, provide a nanoplatform for loading disease-relevant antigen, adjuvant and DC-targeting molecules simultaneously. However, it is yet not fully understood how liposomal formulations affect uptake by DCs and DC function. Here, we examined monocyte-derived DC (moDC) and skin DC uptake of six different liposomal formulations, together with their DC-modulating effect. Contrary to literature, we show using imaging flow cytometry that anionic or neutral liposomes are taken up more efficiently than cationic liposomes by moDCs, or by skin DCs after intradermal injection. None of the formulations yielded significant modulation of DC function as determined by the upregulation of maturation markers and cytokine production. These results suggest that anionic liposomes would be more suitable as vaccine carriers for a dermal application.
Original languageEnglish
Pages (from-to)1081-1091
Number of pages11
JournalJournal of pharmaceutical sciences
Volume111
Issue number4
Early online date2022
DOIs
Publication statusPublished - Apr 2022

Keywords

  • Cationic lipid(s)
  • Cell culture
  • Drug delivery system(s)
  • Immunogenicity
  • Immunology
  • Immunotherapy
  • Lipid nanoparticle(s)
  • Liposome(s)
  • Nanomedicine
  • Skin

Cite this